Routine use of loop diuretics during morcellation does not improve holmium laser enucleation of the prostate outcomes
A prospective, double-blind, randomized controlled trial
DOI:
https://doi.org/10.5489/cuaj.9842Keywords:
HOLEP, Lasix, BPHAbstract
Introduction: Loop diuretics have been administered historically during morcellation to promote urine production postoperatively and to minimize the impact of fluid absorption during holmium laser enucleation of the prostate (HoLEP) procedures. Despite the widespread use of furosemide, no prior study has examined the effects of this medication on postoperative outcomes, including same-day discharge (SDD), same-day trial of void (SDTOV), re-admission rates, or fluid overload. We sought to compare outcomes of HoLEP with and without the use of an intraoperative furosemide.
Methods: From January 2023 to June 2023, we prospectively randomized 138 patients undergoing HoLEP 1:1 to receive or not receive 20 mg of IV furosemide during morcellation (STU00217795). Our primary outcome was to compare rates of SDD between those who receive furosemide at time of HoLEP vs. controls. Secondary outcomes included intraoperative efficiencies and postoperative clinical outcomes.
Results: There was no difference in demographics and prostate features between patients randomized to furosemide (n=69) vs. controls (n=69). Patients receiving furosemide were less likely to undergo a SDTOV attempt (furosemide: 81.6% vs. control: 97.0%, p=0.005) and to achieve SDD (furosemide: 63.6% vs. control: 81.8%, p=0.019). There was no difference between the cohorts in the rates of failed SDTOV, mean length of stay (LOS), or mean catheterization time. No patients in either group experienced symptomatic postoperative fluid overload.
Conclusions: IV furosemide administered during HoLEP does not improve rates of SDD, SDTOV, LOS, duration of catheterization, or adverse event rates. Routine intraoperative furosemide administration does not appear to have a role within a contemporary HoLEP treatment pathway.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.




